logo-loader
Polarean Imaging PLC

New System Order

/**/ sup{font-size:80%}h1{margin-top:24.0pt;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;line-height:115%;font-size:14.0pt;font-family:"Calibri Light","sans-serif";color:#2F5496;font-weight:bold;}p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: #0563C1 }visited{ color: #954F72 } .au{size:596.0pt 842.0pt;margin:78.0pt 57.0pt 14.0pt 51.0pt;}div.au{}p.cq{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin: 0cm; margin-bottom: .0001pt; text-align: center}span.co{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}span.cn{font-size:11.0pt; font-family:"Calibri","sans-serif";color:black}p.cr{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; margin: 0cm; margin-bottom: .0001pt; text-align: center}p.cs{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;line-height:normal;text-autospace:none}span.ck{color:black}p.ct{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;line-height:normal}span.ch{letter-spacing:-.05pt} span.cg{letter-spacing:1.6pt}span.cf{letter-spacing:1.65pt}span.ce{letter-spacing:-.1pt}span.cd{letter-spacing:1.5pt}span.cc{letter-spacing:-.2pt}p.cu{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm}p.cv{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-div: italic; line-height: normal; margin-bottom: 0cm; text-align: justify}p.cw{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; text-align: justify}table.cx{width:492.05pt;margin-left:-5.4pt;border-collapse:collapse}tr.bv{height:19.75pt} td.by{width:220.05pt;padding:0cm 5.4pt 0cm 5.4pt; height:19.75pt}td.bw{width:250.4pt;padding:0cm 5.4pt 0cm 5.4pt; height:19.75pt}p.cy{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";line-height: normal; margin-bottom: 0cm; text-align: right}tr.bq{height:18.0pt}td.bt{width:303.35pt;padding:0cm 5.4pt 0cm 5.4pt; height:18.0pt}p.cz{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;line-height: normal}td.br{width:167.1pt;padding:0cm 5.4pt 0cm 5.4pt; height:18.0pt}p.da{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-div: italic; line-height: normal; margin-bottom: 0cm; text-align: right}td.bp{width:303.35pt;padding:0cm 5.4pt 0cm 5.4pt; height:19.75pt}td.bo{width:167.1pt;padding:0cm 5.4pt 0cm 5.4pt; height:19.75pt} tr.bk{height:20.1pt}td.bn{width:303.35pt;padding:0cm 5.4pt 0cm 5.4pt; height:20.1pt}td.bl{width:167.1pt;padding:0cm 5.4pt 0cm 5.4pt; height:20.1pt}p.db{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; text-align: right}tr.bh{height:39.85pt}td.bj{width:303.35pt;padding:0cm 5.4pt 0cm 5.4pt; height:39.85pt}td.bi{width:167.1pt;padding:0cm 5.4pt 0cm 5.4pt; height:39.85pt}td.bg{width:167.95pt;padding:0cm 5.4pt 0cm 5.4pt; height:19.75pt}td.bf{width:302.5pt;padding:0cm 5.4pt 0cm 5.4pt; height:19.75pt}td.be{width:194.0pt;padding:0cm 5.4pt 0cm 5.4pt; height:39.85pt} td.bd{width:276.45pt;padding:0cm 5.4pt 0cm 5.4pt; height:39.85pt}td.bc{border:none}p.dc{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-div: italic; margin: 0cm; margin-bottom: .0001pt}span.ba{font-size: 11.0pt;font-family:"Calibri","sans-serif"}p.dd{margin-top:0cm;margin-right:0cm;margin-bottom:12.0pt;margin-left:42.55pt;text-align:justify;line-height:120%;font-size:11.0pt;font-family:"Arial","sans-serif";margin:0cm;margin-bottom:.0001pt;line-height:normal}span.ay{font-family:"Calibri","sans-serif"}p.de{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;text-align:justify}span.aw{font-size:11.0pt;font-family:"Calibri","sans-serif"} /**/
RNS Number : 1929B
Polarean Imaging PLC
05 June 2019
 

Polarean Imaging Plc 

("Polarean" or the "Company")

 

New System Order

 

Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary drug-device combination product for the magnetic resonance imaging (MRI) market, announces the Company has received its latest research unit order for a 9820 Xenon Polariser system from The Hospital for Sick Children ("SickKids") in Toronto www.sickkids.ca.  

 

SickKids is a major paediatric research and teaching hospital and already has an earlier model Polarean polariser (which was recently upgraded). This new unit will expand SickKids' ongoing paediatric research programme using hyperpolarised gas imaging. Their order was enabled by a grant from the Canada Foundation for Innovation ("CFI") www.innovation.ca/about. Following receipt of this order, the total number of the Company's polarisers that are either installed or on order is 24.

 

Richard Hullihen, CEO of Polarean, said: "We are very happy to extend our long-standing relationship with SickKids Hospital in Toronto who work tirelessly on the paediatric applications of hyperpolarised xenon imaging for this important patient population."

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

 

Enquiries:

 

Polarean Imaging plc

www.polarean.com / www.polarean-ir.com

Richard Hullihen, Chief Executive Officer

Via Walbrook PR

Richard Morgan, Chairman


 


SP Angel Corporate Finance LLP

Tel: +44 (0)20 3470 0470

David Hignell / Lindsay Mair / Jamie Spotswood (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)




Walbrook PR

Tel: +44 (0)20 7933 8780 or [email protected]

Paul McManus / Anna Dunphy

 

Mob: +44 (0)7980 541 893 / +44 (0)7879 741 001

 

 

About Polarean (www.polarean.com)

 

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue generating, medical drug-device combination companies operating in the high resolution medical imaging market.

 

The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas (129Xe) as an imaging agent to visualise ventilation and gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung and the bloodstream and in the pulmonary vasculature. Xenon gas exhibits solubility and signal properties that enable it to be imaged within other tissues and organs.

 

The Group operates in an area of significant unmet medical need and the Group's technology provides a novel diagnostic approach, offering a non-invasive and radiation-free functional imaging platform which is more accurate and less harmful to the patient than current methods. The annual burden of pulmonary disease in the US is estimated to be over US$150 billion.

 

The Group also develops and manufactures high performance MRI radiofrequency (RF) coils which are a required component for imaging 129Xe in the MRI system. The development of these coils by the Group facilitates the adoption of the Xenon technology by providing application-specific RF coils which optimise the imaging of 129Xe in MRI equipment for use as a medical diagnostic as well as a method of monitoring the efficacy of therapeutic intervention.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCGSGDLLBGBGCU

Quick facts: Polarean Imaging PLC

Price: £0.24

Market: AIM
Market Cap: £27.64 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Polarean Imaging begins enrolment for phase III clinical...

Polarean Imaging PLC's (LON:POLX) Richard Hullihen tells Proactive London's Andrew Scott they're on track to complete recruitment to their phase III clinical trial by the end of the current quarter following the enrolment of the first patient at the third site. The company’s drug-device...

2 weeks, 3 days ago

RNS

Phase III Clinical Trials update

2 weeks, 4 days ago

Total Voting Rights

3 weeks, 2 days ago

Holding(s) in Company

3 weeks, 3 days ago

Holding(s) in Company

3 weeks, 3 days ago

Holding(s) in Company

3 weeks, 4 days ago

Result of AGM

4 weeks, 1 day ago

Exercise of Warrants

4 weeks, 2 days ago